ABVX Abivax SA American
Company Analysis
Latest News
Abivax Draws 12 Buy Ratings as Analysts See 84% Upside
Abivax SA received positive reviews from market analysts today, with multiple reports pointing to significant upside potential. One comprehensive analysis...
🔴 Abivax is trading 4.16% down today amid biotech-sector weakness
Abivax is trading 4.16% lower at $87.91 as biotech-sector weakness weighs on shares. - The provided sector context shows XBI down 2.50% during the session. -...
🔴 Abivax is trading 4.51% down today with no specific catalyst identified
Abivax is trading 4.51% down at $94.55 on October 1, 2026; the available evidence does not establish a specific catalyst. - Its September 30 release announced...
🟢 Abivax is trading 4.38% up — no clear catalyst identified
Abivax is trading up 4.38% at $95.05 on September 28, 2026, with no specific catalyst established. - The broad market is weaker, and the supplied market data...
Abivax leads Guggenheim's biotech picks, citing strong obefazimod outlook
Guggenheim Securities named Abivax its top biotech investment idea. The firm reiterated a Buy rating for the company. Analysts set a price target of $175. This...
🔴 Abivax is trading 4.1% down today after first-half EPS missed consensus
Abivax is trading at $94.30, down 4.1%, as investors digest its September 21 first-half results. - Net loss widened to €165.9 million, and EPS of $(2.43)...
🔴 Abivax is trading 4.3% down today after wider first-half losses
Abivax is trading 4.3% down now at $99 after September 21, 2026 results showed a €165.9 million first-half net loss, versus €100.8 million a year earlier,...
Abivax reports first half 2026 loss of €166M while extending cash runway through 2029
Abivax reported its financial results for the first half of 2026, characterized by a significant increase in operational investment as the company advances its...
Abivax SA American Q2 2026 Earnings Preview: What Analysts Expect on September 21, 2026
Abivax SA American is expected to report a Q2 2026 revenue consensus of $1.86 million and an EPS loss of $1.08, while its current stock price of $118.64 trades...
🟢 Abivax rises 4.5% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Abivax is trading 4.7% down today as biotech shares weaken
Abivax is trading 4.7% down now at $101.60, primarily as biotech shares weakened after disappointing pelacarsen trial results intensified concerns about...
🔴 Abivax falls 4.0% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Abivax is trading 4.1% down today with no confirmed company-specific announcement
Abivax is trading at $113.76 (-4.11%), with no confirmed company-specific announcement explaining the September 14 decline. - Abivax’s half-year results...
🔴 Abivax is trading 4.05% down today as hotter-than-expected PPI pressured growth stocks
Abivax is trading at $114.62 (-4.05%) after hotter-than-expected producer inflation pressured equities and rate-sensitive growth stocks. - The S&P 500, Nasdaq...
🟢 Abivax is trading 4.1% up today despite a weaker broader U.S. market
Abivax is trading 4.1% up now at $119.50, with no clear company-specific catalyst identified. - No clear company-specific announcement dated September 8,...
🟢 Abivax is trading 4.02% up today as XBI gains 2.75%
Abivax is trading 4.02% up now at $115.54, with the move primarily supported by biotechnology-sector strength. - XBI is up 2.75%, alongside a broadly positive...
RA Capital Discloses New $151M Stake in Abivax (ABVX)
RA Capital Management, a prominent life sciences investment firm, revealed a new position in Abivax SA (ABVX). According to its quarterly ownership report, the...
Perceptive Advisors Slashes ABIVAX (ABVX) Stake by 78%
Life sciences investment firm Perceptive Advisors significantly reduced its holdings in ABIVAX SA (ABVX) during the second quarter of 2026, cutting its...
Baker Bros. Advisors exits its position in clinical-stage biotech Abivax
In a quarterly filing that reflects its portfolio as of June 30, 2026, prominent life sciences investor Baker Bros. Advisors disclosed it had completely sold...